CClinicalTrials.gg
CompletedNCT01534507Updated Aug 13, 2014

Small and Large Bowel Transit Tests Using MRI (Study 1)

An observational study in Irritable Bowel Syndrome, sponsored by University of Nottingham. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-08-13.

Sponsored by University of Nottingham · Observational

Study type
Observational
Time perspective
Prospective
Enrollment
108
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Irritable bowel syndrome, (IBS) is a common functional disorder of the gut that can be quite disabling to patients. The most common symptoms of IBS are abdominal pain or discomfort along with erratic changes in bowel habit of diarrhoea, constipation or a mixture of the two (referred to as IBS subtypes). Despite much research efforts to further understand the pathophysiology of IBS; as yet no specific biomarkers/definitive measurements have been identified that can be use to aid the diagnosis and reduce the need for unnecessary, unpleasant and expensive tests.

Evidence shows that anxiety plays a part in IBS and can speed up transit time in the small bowel. In this study, the investigators hypothesise that since anxiety is a common feature of IBS, then fast small bowel transit is likely to be found in all subtypes of IBS and the difference in stool frequency and consistency in IBS subgroups are therefore likely to reflect differences in colonic function. The investigator wish to test this by measuring both small and large bowel transit times using Magnetic Resonance Imaging (MRI) and validate the results of the MRI with two methods currently used in clinical practice -The previously validated lactose-C13 Ureide breath test (for small bowel transit) and the standard radio-opaque pellet method to assess the whole gut transit (WGT) time.

Read the detailed description

The investigator has 2 main parts in this study i.e. Study 1 and Study 2.

As part of study 1, the investigator would like to recruit up to 5 healthy volunteers as a pilot study to optimise measurement and analysis of the Lactose-C13 Ureide breath test along with MRI scannings at regular intervals.

Following from this, the investigator would like assess the feasibility and reproducibility of using MRI imaging to assess gastrointestinal transit. The investigator would like to recruit 21 healthy volunteers to measure orocaecal transit time (OCTT) and whole gut transit(WGT)using the conventional method of Lactose-C13 Ureide breath test for OCTT and the Metcalf method using standard radio-opaque pellet method for WGT and compare them will MRI imaging. Once this has been analysed and the best method for each OCTT and WGT have been decided, these methods would be applied in Study 2.

In study 2, the investigator would like to recruit 30 healthy volunteers, 30 patients with diarrhoea predominantly Irritable Bowel Syndrome, 30 patients with constipation predominantly Irritable Bowel Syndrome and 30 patients with Mixed irritable Bowel Syndrome. The best methods from study 1 for OCTT and WGT will be applied here to assess gastrointestinal transit on these subjects. Based on the first study, the best method to assess OCTT is the Lactose-C13 Ureide breath test and for the WGT, the best method is the MRI marker capsules. Participants will need to fill in questionnaires to assess their stress levels and to fill in symptom questionnaires during the study day.

02

Conditions studied

  • Irritable Bowel Syndrome
03

In context

Irritable Bowel Syndrome

1,062 studies on the registry are indexed under Irritable Bowel Syndrome; 190 are open to participants now.

This study's enrollment of 108 is below the median of 150 across 178 observational studies indexed under Irritable Bowel Syndrome.

Browse Irritable Bowel Syndrome studies →

Lead sponsor

University of Nottingham is the lead sponsor of 455 studies on the registry; 77 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy volunteers will be selected via poster advertisement Participants with Irritable Bowel Syndrome will be selected from the gastroenterology clinics /poster advertisement

Eligibility criteria

Study 1

Inclusion Criteria

  • 26 healthy volunteer
  • Age 18-75 years old
  • Non-smoker
  • Able to give informed consent

Exclusion Criteria

  • Lactose intolerant
  • Any history of gastrointestinal surgery on the small bowel (excluding appendicectomy)
  • Pregnancy
  • contraindications for MRI scanning i.e. metallic implants, pacemakers, history of metallic foreign body in eye(s) and penetrating eye injury alcohol dependence
  • serious concomitant illness as judged by the investigators
  • use of drugs known to alter GI motility including opiates, anti-depressants, selective serotonin reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, phenothiazines, benzodiazepines, calcium channel antagonists during or in the 2 weeks prior to the test
  • inability to lie flat or exceed scanner limits of weight >120kg or abdominal circumference >99cm ; BMI \<18 and >30 kg/m2
  • Poor command of English language
  • Participation of any medical trials for the past 3 months

Study 2:

120 participants consisting of: 30 patients with diarrhoea predominant IBS according to Rome III criteria 30 patients with constipation predominant IBS according to Rome III criteria 30 patients with mixed type IBS according to Rome III criteria 30 healthy volunteers age and sex matched controls

Inclusion criteria

  • Meet the Rome III criteria and the IBS subtypes
  • Age 18-75 years old
  • Able to give informed consent
  • Subjects will undergo a limited screening medical. They will also complete a MRI - safety questionnaire and be given an information sheet
  • Able to give informed consent
  • Subjects will undergo screening medical questionnaire. They will also complete a MRI safety questionnaire and be given an information sheet

Exclusion Criteria

  • Any history of gastrointestinal surgery on the small bowel (excluding appendicectomy)
  • Pregnancy
  • contraindications for MRI scanning i.e. metallic implants, pacemakers, history of metallic foreign body in eye(s) and penetrating eye injury
  • alcohol dependence
  • serious concomitant illness as judged by the investigators
  • use of drugs known to alter GI motility including opiates, , monoamine oxidase inhibitors, phenothiazines, benzodiazepines, calcium channel antagonists during or in the 2 weeks prior to the test
  • Selective serotonin reuptake inhibitors or low dose tricyclic antidepressants will be recorded but will not be an exclusion
  • No recent antibiotic treatment past 2 weeks
  • inability to lie flat or exceed scanner limits of weight >120kg or abdominal circumference >99cm; BMI \<18 and >30 kg/m2
  • Poor command of English language
  • Participation of any medical trials for the past 3 months
05

Study design

Time perspective
Prospective
Enrollment
108 participants (actual)
Biospecimen retention
Samples without dna

Groups and cohorts

  • Healthy Volunteer 1 (Group 1)

    For study 1 : Up to 5 healthy volunteers for the initial pilot study and further 21 healthy volunteers for the main study 1

  • Group 2 for study 2

    Patients with diarrhoea due to irritable bowel syndrome

  • Group 3 for study 2

    Patients with constipation due to irritable bowel syndrome

  • Group 4 for study 2

    Patients with mixed bowel habit due to irritable bowel syndrome

  • Group 5 for study 2: Healthy volunteer 2

    Healthy participants to act as control

06

What researchers measure

Primary outcomes

  1. Study 1:Correlation between mean orocaecal transit time as assessed by MRI and lactose C13-ureide

    MRI:Orocaecal transit time (OCTT) can be measured by the first scan showing arrival of the head of a meal in the ascending colon Lactose C13-Ureide breath test:Orocaecal transit time will be taken as the time at which a significant increase from background in breath 13C was seen.

    Time frame: 9 hours

  2. Study 1: Correlation between colonic transit as assessed by from the geometric centre of the PTFE capsule at time 24 and 48 hours and Metcalf Radio-opaque marker method

    Colonic transit using MRI will be measure by assessing the geometric centre position in colon/small bowel. Whole gut transit time using the Metcalf method of Radio-opaque Marker method would be estimated by counting the number of pellets remaining in the colon in an abdominal x-ray taken in day 4 \* 1.2

    Time frame: 72 hours

  3. Study 2: Fasting small bowel water content

    Fasting small bowel water content (SBWC) in the 3 subgroups of Irritable Bowel Syndrome (IBS) compared to healthy controls

    Time frame: 1 hour

Secondary outcomes

  1. Study 1:To assess reproducibility of the using MRI for orocaecal transit time and colonic transit time

    In study 1, the orocaecal transit time and colonic transit time would be repeated twice with a week break in between to assess reproducibility of the MRI.

    Time frame: 21 days

  2. Study 2: Orocaecal transit time using lactose C13-ureide

    Orocaecal transit time in the 3 subgroups of IBS versus healthy control using the best method from study 1 which is the lactose C13-Ureide breath test

    Time frame: 9 hours

  3. Study 2: Area under the curve (AUC) post prandial SBWC

    Time frame: 9 hours

  4. Study 2: Ascending colon water content (ACWC) and colonic water index (CWI)

    Time frame: 9 hours

  5. Study 2: Colonic volumes both fasting and post prandial (divided into ascending transverse and descending colon)

    Time frame: 9 hours

  6. Study 2: Whole gut transit time assess by MRI marker capsule from study 1

    The best method to assess the whole gut transit time based on study 1 was the use of the MRI marker capsule at time 24hours

    Time frame: 24 hours

  7. Study 2: Correlation between the Hospital Anxiety & Depression Scale (HADS) and other measures of anxiety and stress score and (a) Oro-caecal transit time and (b)whoe gut transit time

    Time frame: 9hours

07

Study locations

1 site
  • University of Nottingham
    Nottingham, Notts NG7 2UH, United Kingdom
08

References and documents

Publications

  • Metcalf AM, Phillips SF, Zinsmeister AR, MacCarty RL, Beart RW, Wolff BG. Simplified assessment of segmental colonic transit. Gastroenterology. 1987 Jan;92(1):40-7. doi: 10.1016/0016-5085(87)90837-7. PubMed 3023168 ↗
  • Chaddock G, Lam C, Hoad CL, Costigan C, Cox EF, Placidi E, Thexton I, Wright J, Blackshaw PE, Perkins AC, Marciani L, Gowland PA, Spiller RC. Novel MRI tests of orocecal transit time and whole gut transit time: studies in normal subjects. Neurogastroenterol Motil. 2014 Feb;26(2):205-14. doi: 10.1111/nmo.12249. Epub 2013 Oct 25. PubMed 24165044 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01534507
Lead sponsor
University of Nottingham
Responsible party
Sponsor
First posted
Feb 16, 2012
Start date
Nov 2011
Primary completion
Aug 2014
Completion
Aug 2014
Last update
Aug 13, 2014

Study contacts

Robin Spiller, MD FRCP
study director · University of Nottingham
Ching Lam, MBchB MRCP
principal investigator · University of Nottingham

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion